Who Owns Castle Biosciences Company?

Castle Biosciences Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Castle Biosciences?

Unraveling the ownership structure of Castle Biosciences SWOT Analysis is key to understanding its future. From its inception in 2008 to its 2019 IPO, the company's ownership has undergone a significant transformation. This shift has major implications for its strategic direction and the influence of various stakeholders.

As a publicly traded entity, understanding who owns Castle Biosciences is more critical than ever. This exploration will dissect the ownership dynamics, including the roles of Castle Biosciences investors, institutional players, and insider ownership. We'll also look at the impact of these ownership changes on the company's governance and strategic decisions, providing insights for investors and stakeholders alike, including the Castle Biosciences CEO and leadership.

The company, officially known as Castle Biosciences, was established in 2008. The founder of Castle Biosciences was Derek Maetzold. He currently serves as the President and Chief Executive Officer.

Early funding for Castle Biosciences came from various sources, including seed and angel investors. The company secured a total of $62 million across 17 funding rounds before its IPO. This funding supported its growth and development.

Early investors played a significant role in the company's early growth. HealthQuest Capital, Mountain Group Capital and Affiliates, and Longfellow Venture Partners were among the initial investors. These investments helped shape the company's direction.

Founding

Castle Biosciences was founded in 2008 by Derek Maetzold. He continues to be a key figure in the company's leadership.

Early Funding

Before its IPO, Castle Biosciences raised a total of $62 million across 17 funding rounds. These rounds included seed, early-stage, late-stage, and debt financing.

Key Investors

Early investors included HealthQuest Capital, Mountain Group Capital and Affiliates, and Longfellow Venture Partners. These investors played a crucial role in the company's early development.

Board Influence

Garheng Kong, Managing Partner of HealthQuest Capital, joined the board of directors. This reflects the influence of early institutional investment.

Ownership Details

Specific details on initial equity splits or vesting schedules are not available in the public records. This is typical for early-stage companies.

Financial Backing

The company's financial success is detailed in Brief History of Castle Biosciences. This includes the funding rounds that supported its growth.

The early investment rounds and the involvement of firms like HealthQuest Capital highlight the importance of institutional backing. These investments helped fuel the company's growth. The company's journey from its founding to its current status as a publicly traded entity involved several key financial milestones. The early investors and their influence on the board of directors played a crucial role in shaping the company's direction.

Key Takeaways

Understanding the early ownership and investment landscape provides insights into the company's foundation.

• Derek Maetzold founded Castle Biosciences in 2008.
• The company raised $62 million before its IPO.
• HealthQuest Capital, Mountain Group Capital, and Longfellow Venture Partners were early investors.
• Garheng Kong of HealthQuest Capital joined the board.

Castle Biosciences SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Castle Biosciences' ownership structure began with its initial public offering (IPO) on July 25, 2019. The IPO, priced at $16.00 per share, raised approximately $73.6 million. This event marked the transition of the company from private to public ownership, opening the door for institutional and retail investors to acquire shares. The IPO established the initial ownership base and set the stage for future shifts in the ownership landscape.

Since its IPO, the ownership of Castle Biosciences has seen significant changes, particularly with the increasing presence of institutional investors. As of June 11, 2025, the company's market capitalization stands at $532 million, reflecting the impact of market performance and investor confidence. The growth in institutional ownership, holding between 61.70% and 89.33% of the shares, indicates a shift toward more significant influence from large investment firms. This trend influences the company's strategic direction and governance practices.

As of March 31, 2025, major institutional shareholders include BlackRock, Inc. with 2,983,540 shares, and Vanguard Group Inc with 2,047,565 shares. Derek J. Maetzold, the President and CEO, holds 801,338 shares, representing a significant insider stake. These ownership dynamics highlight the influence of institutional investors on the Castle Biosciences stock and the importance of insider ownership in the company's strategic direction. The balance between institutional, insider, and retail ownership shapes the company's trajectory in the competitive biotechnology market.

Ownership Dynamics of Castle Biosciences

The ownership structure of Castle Biosciences is a mix of institutional, retail, and insider holdings, with institutional investors holding a significant majority.

• Institutional investors hold between 61.70% and 89.33% of the company's stock.
• Insiders, including the CEO, hold a notable percentage of the shares.
• The IPO in 2019 marked the beginning of its public ownership.
• Market capitalization reached $532 million as of June 11, 2025.

Castle Biosciences PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Castle Biosciences oversees the company's strategic direction and corporate governance. Derek J. Maetzold, the President and CEO, is a director, indicating his direct involvement in the company's leadership. Garheng Kong, a Managing Partner from HealthQuest Capital, also sits on the board, reflecting the influence of early investors. The board's composition includes a mix of individuals representing major shareholders and independent seats, ensuring diverse perspectives in decision-making. Understanding the Competitors Landscape of Castle Biosciences is crucial for investors.

The board's structure includes a standard voting model, with directors elected for three-year terms. The 2025 Proxy Statement provides detailed information on board structure and director nominations. The Audit Committee oversees the company's corporate responsibility program, as amended in April 2021. Stockholders can nominate directors and propose business at annual meetings, provided they adhere to advance notice procedures. There is no indication of dual-class shares or special voting rights that would grant outsized control to particular individuals or entities.

Voting Power and Board Structure

The board of directors at Castle Biosciences plays a critical role in governance, with directors elected for three-year terms. Vacancies are filled by a majority vote of the existing directors. Stockholders can nominate directors, following advance notice procedures.

• Derek J. Maetzold, President and CEO, is a director.
• Garheng Kong, from HealthQuest Capital, is on the board.
• The Audit Committee oversees corporate responsibility.
• No dual-class shares or special voting rights are mentioned.

Castle Biosciences Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the last few years, Castle Biosciences' financial performance and strategic moves have influenced its ownership dynamics. In 2024, the company reported a full-year revenue of $332 million, which is a significant 51% increase compared to 2023. The company also delivered a total of 96,071 test reports, marking a 36% rise. For the first quarter of 2025, revenue increased by 21% compared to the same period in 2024, reaching $88 million. This growth led to an upward revision of its full-year 2025 revenue guidance to $287-297 million.

Strategically, the company announced in May 2025, an agreement to acquire Previse (Capsulomics, Inc.), a gastrointestinal health company, expanding its GI testing portfolio. This follows the October 2021 acquisition of Cernostics, Inc., specializing in spatial biology and AI-driven image analysis for Barrett's esophagus. These acquisitions reflect the company’s commitment to growth and innovation, which may impact the interests of Castle Biosciences investors.

Institutional ownership remains a key aspect of Castle Biosciences ownership. In Q4 2024, there was considerable activity among institutional investors adjusting their positions. While some increased their stakes, others decreased theirs. The trend of insider selling, particularly by key executives, is a notable aspect of recent ownership changes. These shifts, along with the company's focus on operational excellence and strategic opportunities, are aimed at driving stockholder value in 2025 and beyond, making the company a subject of interest to those tracking Castle Biosciences stock.

Key Development

Acquisition of Previse (Capsulomics, Inc.) in May 2025 to expand GI testing portfolio.

Financial Performance

Full-year 2024 revenue of $332 million, a 51% increase from 2023; Q1 2025 revenue up 21% year-over-year.

Ownership Activity

Significant institutional investor adjustments in Q4 2024, with share additions and reductions.

Insider Trading

Executive sales of shares over the past six months, including the President and CEO.

Castle Biosciences Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs